Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

LYEL

Lyell Immunopharma Inc

Apr 10 • 04:00PM ET

22.39

-1.46 -6.12 %

Healthcare • Biotechnology • USA • NASD

Peers: ALLO FATE ADPT IGMS AFMD KURA NKTR ZLAB TGTX XBIT

| Held by: VTI VXF SCHA IBB VHT AVSC DFAS DFMC SCHB PRFZ

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-15.17	Insider Own	65.95%	Shs Outstand	21.25M	Perf Week	5.56%
Market Cap	521.85M	Forward P/E	-	EPS next Y	-9.16	Insider Trans	6.68%	Shs Float	7.94M	Perf Month	-10.94%
Enterprise Value	325.62M	PEG	-	EPS next Q	-2.28	Inst Own	13.99%	Short Float	14.34%	Perf Quarter	-7.86%
Income	-274.45M	P/S	13046.25	EPS this Y	41.10%	Inst Trans	7.24%	Short Ratio	11.37	Perf Half Y	22.62%
Sales	0.04M	P/B	1.92	EPS next Y	3.15%	ROA	-66.06%	Short Interest	1.14M	Perf YTD	-27.26%
Book/sh	11.68	P/C	2.11	EPS next 5Y	26.28%	ROE	-86.98%	52W High	45.00 -50.24%	Perf Year	169.82%
Cash/sh	10.61	P/FCF	-	EPS past 3/5Y	-2.70% 0.99%	ROIC	-94.60%	52W Low	7.65 192.68%	Perf 3Y	-58.07%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-92.48% -65.85%	Gross Margin	-31952.78%	Volatility	7.83% 9.65%	Perf 5Y	-
Dividend TTM	-	EV/Sales	8140.50	EPS Y/Y TTM	42.18%	Oper. Margin	-566038.89%	ATR (14)	1.91	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.28	Sales Y/Y TTM	-40.98%	Profit Margin	-762355.56%	RSI (14)	52.80	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.28	EPS Q/Q	54.02%	SMA20	7.71%	Beta	0.00	Target Price	40.50
Payout	-	Debt/Eq	0.21	Sales Q/Q	-45.45%	SMA50	-1.19%	Rel Volume	1.08	Prev Close	23.85
Employees	161	LT Debt/Eq	0.17	Earnings	Mar 12 AMC	SMA200	18.46%	Avg Volume	100.15K	Price	22.39
IPO	Jun 17, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-246.77% -60.78%	Trades		Volume	108,597	Change	-6.12%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-10-26	Initiated	Needham	Buy	$44
Mar-09-26	Initiated	Citizens	Mkt Outperform	$34
Dec-09-25	Upgrade	H.C. Wainwright	Neutral → Buy	$45
Oct-30-24	Downgrade	BofA Securities	Buy → Underperform	$6 → $1
Jun-27-24	Downgrade	H.C. Wainwright	Buy → Neutral	$6 → $1
Aug-28-23	Downgrade	JP Morgan	Overweight → Neutral	$15 → $5
Nov-14-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$15 → $7
Nov-11-22	Downgrade	Goldman	Buy → Neutral	$13 → $7
Oct-17-22	Initiated	H.C. Wainwright	Buy	$12
Jul-12-21	Initiated	Morgan Stanley	Overweight	$25
Jul-12-21	Initiated	JP Morgan	Overweight	$22
Jul-12-21	Initiated	Goldman	Buy	$30
Jul-12-21	Initiated	BofA Securities	Buy	$25

Show Previous Ratings

Apr-07-26 08:00AM	Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-12-26 06:10PM	Lyell Immunopharma: Q4 Earnings Snapshot (Associated Press Finance) -14.23%
04:05PM	Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results (GlobeNewswire)
Mar-09-26 08:00AM	Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer (GlobeNewswire) +13.54%
Feb-23-26 08:00AM	Lyell Immunopharma Announces Participation in March Investor Conferences (GlobeNewswire) +6.12%
06:00AM	Loading…
Feb-13-26 06:00AM	Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs (BioPharma Dive)
Feb-12-26 07:30AM	Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma (GlobeNewswire)
Dec-26-25 02:33AM	The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar (Zacks) -9.09%
Dec-24-25 10:51AM	4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow (Zacks)
Dec-19-25 07:44AM	Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 (PR Newswire)
Dec-07-25 04:30PM	Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition (GlobeNewswire)
Nov-12-25 05:40PM	Lyell Immunopharma: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 (GlobeNewswire)
05:20AM	Metagenomi, Ovid CEOs step aside; Cogent soars on unprecedented stomach cancer data (BioPharma Dive)
Nov-11-25 08:44AM	Lyell acquires worldwide rights from ICT to CAR T-cell therapy (Pharmaceutical Technology)
07:30AM	Loading…
Nov-10-25 07:30AM	Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer (GlobeNewswire)
Nov-03-25 09:00AM	Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition (GlobeNewswire)
Sep-03-25 08:00AM	Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee (GlobeNewswire)
Sep-02-25 04:05PM	Lyell Immunopharma Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-12-25 06:17PM	Lyell Immunopharma: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025 (GlobeNewswire)
Jul-29-25 03:46PM	Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments (PR Newswire) -6.26%
Jul-25-25 08:00AM	Lyell Immunopharma Announces up to $100 Million Equity Private Placement (GlobeNewswire) +19.31%
Jun-23-25 05:00PM	Lyell Immunopharma to Participate in the H.C. Wainwright "HCW@Home" Series (GlobeNewswire) +6.62%
Jun-18-25 07:12AM	Lyell reports new clinical data from trial of large B-cell lymphoma therapy (Clinical Trials Arena)
Jun-17-25 06:30AM	Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma (GlobeNewswire)
Jun-09-25 04:05PM	Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments (GlobeNewswire) -13.39%
Jun-04-25 04:05PM	Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference (GlobeNewswire) +68.59% -14.92%
May-13-25 05:49PM	Lyell Immunopharma: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025 (GlobeNewswire)
09:00AM	Loading…
May-01-25 09:00AM	Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025 (GlobeNewswire)
Apr-15-25 09:00AM	Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma (GlobeNewswire)
Mar-28-25 10:54AM	Is Lyell Immunopharma, Inc. (LYEL) the Cheapest Stock Insiders Are Buying In March? (Insider Monkey) -8.83%
Mar-11-25 04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024 (GlobeNewswire)
Feb-18-25 04:05PM	Lyell Immunopharma Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jan-22-25 12:00PM	Lyell Immunopharma (LYEL) Upgraded to Strong Buy: Here's Why (Zacks)
Jan-09-25 09:00AM	Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference (GlobeNewswire)
Dec-31-24 09:35AM	After Plunging -37.9% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL) (Zacks)
Dec-30-24 09:35AM	After Plunging -31.22% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL) (Zacks)
Dec-13-24 09:35AM	Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround (Zacks) -11.37%
Dec-09-24 09:00PM	Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting (GlobeNewswire)
Nov-14-24 12:00PM	Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-07-24 05:22PM	Lyell Immunopharma: Q3 Earnings Snapshot (Associated Press Finance) -17.57%
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024 (GlobeNewswire)
Nov-05-24 09:30AM	Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-24 04:00PM	Lyell Immunopharma Completes Acquisition of ImmPACT Bio (GlobeNewswire) +11.88% +16.63%
Oct-30-24 11:16AM	Lyell shares down as BofA double downgrades to Sell (Investing.com) -9.47%
Oct-25-24 11:56AM	Lyell goes all in on CAR-T therapies, buys ImmPACT Bio and trims pipeline (Pharmaceutical Technology) -14.95%
Oct-24-24 04:00PM	Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies (GlobeNewswire) -5.22%
01:54PM	Lyell, in search of a turnaround, to buy cell therapy startup ImmPact (BioPharma Dive)
Oct-04-24 09:00AM	Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Sep-24-24 04:05PM	Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day (GlobeNewswire) -7.53%
Aug-28-24 04:05PM	Lyell Immunopharma Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-07-24 05:41PM	Lyell Immunopharma: Q2 Earnings Snapshot (Associated Press Finance) +6.38%
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024 (GlobeNewswire)
Aug-06-24 08:00AM	3 Biotech Stocks to Sell in August Before They Crash & Burn (InvestorPlace)
Jun-26-24 02:44PM	Lyell Immunopharma Shares Plunge On One Patient Death In CAR-T Cell Therapy Cancer Trial (Benzinga) -36.03%
07:00AM	Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology (GlobeNewswire)
Jun-03-24 04:05PM	Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference (GlobeNewswire) -5.68%
May-07-24 04:05PM	Lyell Immunopharma to Participate in BofA Securities Health Care Conference (GlobeNewswire)
May-06-24 10:53PM	LYEL Stock Earnings: Lyell Immunopharma Beats EPS for Q1 2024 (InvestorPlace) +7.63%
01:34PM	Lyell Immunopharma Shares Rise After Q1 Net Loss Narrows (MT Newswires)
08:23AM	Lyell Immunopharma: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024 (GlobeNewswire)
Mar-19-24 10:00AM	CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB) (GlobeNewswire)
Mar-07-24 12:00PM	Lyell Immunopharma (LYEL) Is Up 28.45% in One Week: What You Should Know (Zacks)
Mar-05-24 04:30PM	Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting (GlobeNewswire) +5.18%
Feb-28-24 04:44PM	Lyell Immunopharma Inc (LYEL) Reports 2023 Financial Results and Business Highlights (GuruFocus.com)
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023 (GlobeNewswire)
Feb-26-24 04:05PM	Lyell Immunopharma Announces Participation in March Investor Conferences (GlobeNewswire) +9.62% +8.78%
Jan-03-24 04:05PM	Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.69%
Nov-09-23 04:05PM	Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma (GlobeNewswire) -6.81% -24.43%
Nov-07-23 04:33PM	Lyell Immunopharma: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023 (GlobeNewswire)
Oct-31-23 09:00AM	Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing (GlobeNewswire) -7.54%
Sep-27-23 09:00AM	Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Sep-11-23 08:00AM	Cellares and Lyell to Evaluate Automated Manufacturing of Lyells CAR T-Cell Therapy on Cellares Cell Shuttle Platform (GlobeNewswire) +9.89%
Aug-31-23 04:05PM	Lyell Immunopharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-23 07:10PM	Lyell Immunopharma: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023 (GlobeNewswire)
Jul-12-23 08:47AM	Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jul-05-23 04:05PM	Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer (GlobeNewswire) -6.98%
Jun-16-23 10:47AM	Why Shares of Lyell Immunopharma Jumped This Week (Motley Fool) -17.36%
Jun-07-23 04:05PM	Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference (GlobeNewswire) -5.52%
Jun-01-23 07:55AM	Even after rising 12% this past week, Lyell Immunopharma (NASDAQ:LYEL) shareholders are still down 31% over the past year (Simply Wall St.)
May-04-23 07:25PM	Lyell Immunopharma (LYEL) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
06:25PM	Lyell Immunopharma: Q1 Earnings Snapshot (AP Finance)
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023 (GlobeNewswire)
May-02-23 04:05PM	Lyell Immunopharma to Participate in BofA Securities Healthcare Conference (GlobeNewswire) +12.08%
Apr-17-23 07:11AM	There's No Escaping Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) Muted Revenues (Simply Wall St.) +7.63%
Mar-27-23 04:52AM	Aurinia (AUPH) Surges 11.0%: Is This an Indication of Further Gains? (Zacks) +8.96%
Mar-26-23 10:14AM	Lyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold a sizeable 47% stake (Simply Wall St.)
Feb-28-23 08:15PM	Lyell Immunopharma (LYEL) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +11.63%
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022 (GlobeNewswire)
Feb-02-23 06:43AM	Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation (Simply Wall St.) +6.10%
Jan-03-23 04:05PM	Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.55%
Dec-23-22 06:36AM	Lyell Immunopharma (NASDAQ:LYEL) investors are sitting on a loss of 63% if they invested a year ago (Simply Wall St.)
Dec-16-22 10:48AM	Lynn Seely steps into top role at cancer-fighting company Lyell Immunopharma (American City Business Journals)
Dec-15-22 07:00AM	Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer (GlobeNewswire) -7.87%
Dec-09-22 09:35AM	Lyell Immunopharma (LYEL) Loses 21.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -9.90%

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ARCH Venture Partners IX, LLC	10% Owner	Mar 06 '26	Buy	25.61	488,090	12,499,985	1,426,528	Mar 09 04:36 PM
ARCH Venture Fund XIII, L.P.	10% Owner	Mar 06 '26	Buy	25.61	488,090	12,499,985	1,426,528	Mar 09 04:34 PM
Seely Lynn	President and CEO	Feb 11 '26	Sale	23.39	7,455	174,372	74,266	Feb 12 08:47 PM
Hill Stephen J.	Chief Operating Officer	Feb 11 '26	Sale	23.39	1,236	28,910	17,795	Feb 12 08:46 PM
Lee Gary K.	Chief Scientific Officer	Feb 11 '26	Sale	23.39	1,671	39,085	16,938	Feb 12 08:44 PM
Hill Stephen J.	Chief Operating Officer	Feb 10 '26	Sale	23.12	109	2,520	19,031	Feb 11 09:05 PM
Lee Gary K.	Chief Scientific Officer	Feb 10 '26	Sale	23.12	147	3,399	18,609	Feb 11 09:04 PM
Seely Lynn	President and CEO	Feb 10 '26	Sale	23.12	438	10,127	81,721	Feb 11 09:03 PM
Bulis Veronica Sanchez	VP, Corporate Controller	Feb 10 '26	Sale	23.12	254	5,872	15,637	Feb 11 09:00 PM
Bulis Veronica Sanchez	VP, Corporate Controller	Dec 24 '25	Sale	38.67	1,136	43,929	8,077	Jan 06 04:02 PM
Bulis Veronica Sanchez	VP, Corporate Controller	Dec 30 '25	Sale	32.32	936	30,252	7,141	Jan 06 04:02 PM
Seely Lynn	President and CEO	Nov 10 '25	Sale	16.11	412	6,637	67,159	Nov 12 08:36 PM
Bulis Veronica Sanchez	VP, Corporate Controller	Nov 10 '25	Sale	16.10	239	3,848	9,213	Nov 12 08:34 PM
Lee Gary K.	Chief Scientific Officer	Nov 10 '25	Sale	16.16	138	2,230	15,366	Nov 12 08:33 PM
Hill Stephen J.	Chief Operating Officer	Nov 10 '25	Sale	16.12	95	1,531	15,750	Nov 12 08:31 PM
Seely Lynn	President and CEO	Aug 21 '25	Sale	10.54	7,257	76,518	67,571	Aug 22 04:07 PM
Hill Stephen J.	Chief Operating Officer	Aug 21 '25	Sale	10.54	1,004	10,586	15,845	Aug 22 04:06 PM
Newton Charles W.	Chief Financial Officer	Aug 21 '25	Sale	10.54	1,453	15,320	15,306	Aug 22 04:03 PM
Lee Gary K.	Chief Scientific Officer	Aug 21 '25	Sale	10.54	1,453	15,320	15,504	Aug 22 04:02 PM
Seely Lynn	President and CEO	Aug 12 '25	Sale	10.34	406	4,197	34,828	Aug 13 09:10 PM
Seely Lynn	President and CEO	Aug 11 '25	Sale	10.53	391	4,116	35,234	Aug 13 09:10 PM
Hill Stephen J.	Chief Operating Officer	Aug 12 '25	Sale	10.34	94	972	8,849	Aug 13 09:09 PM
Hill Stephen J.	Chief Operating Officer	Aug 11 '25	Sale	10.53	91	958	8,943	Aug 13 09:09 PM
Lee Gary K.	Chief Scientific Officer	Aug 12 '25	Sale	10.34	136	1,406	8,957	Aug 13 09:08 PM
Lee Gary K.	Chief Scientific Officer	Aug 11 '25	Sale	10.53	131	1,379	9,093	Aug 13 09:08 PM
Newton Charles W.	Chief Financial Officer	Aug 12 '25	Sale	10.34	136	1,406	8,759	Aug 13 09:06 PM
Newton Charles W.	Chief Financial Officer	Aug 11 '25	Sale	10.53	131	1,379	8,895	Aug 13 09:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LYEL

Lyell Immunopharma Inc

Upgrade your Finviz experience